Elanco Animal Health Inc
For the period ended Dec 31, 2024. Filed Feb 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 25, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
| ELANCO ANIMAL HEALTH INCORPORATED | ||
| (Registrant) | ||
| Date: | February 25, 2025 | /s/ Jeffrey N. Simmons |
|---|---|---|
| Jeffrey N. Simmons | ||
| President and Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
| /s/ Jeffrey N. Simmons | Date: | February 25, 2025 |
|---|---|---|
| Jeffrey N. Simmons | ||
| President and Chief Executive Officer (principal executive officer) and Director | ||
| /s/ Todd S. Young | Date: | February 25, 2025 |
| Todd S. Young | ||
| Executive Vice President, Chief Financial Officer (principal financial officer) | ||
| /s/ James M. Meer | Date: | February 25, 2025 |
| James M. Meer | ||
| Senior Vice President, Chief Accounting Officer (principal accounting officer) | ||
| /s/ Lawrence E. Kurzius | Date: | February 25, 2025 |
| Lawrence E. Kurzius | ||
| Chairman of the Board | ||
| /s/ Kapila Kapur Anand | Date: | February 25, 2025 |
| Kapila Kapur Anand | ||
| Director | ||
| /s/ John P. Bilbrey | Date: | February 25, 2025 |
| John P. Bilbrey | ||
| Director | ||
| /s/ William F. Doyle | Date | February 25, 2025 |
| William F. Doyle | ||
| Director | ||
| /s/ Art A. Garcia | Date: | February 25, 2025 |
|---|---|---|
| Art A. Garcia | ||
| Director | ||
| /s/ Michael J. Harrington | Date: | February 25, 2025 |
| Michael J. Harrington | ||
| Director | ||
| /s/ Paul Herendeen | Date: | February 25, 2025 |
| Paul Herendeen | ||
| Director | ||
| /s/ R. David Hoover | Date: | February 25, 2025 |
| R. David Hoover | ||
| Director | ||
| /s/ Deborah T. Kochevar Ph.D., DVM | Date: | February 25, 2025 |
| Deborah T. Kochevar Ph.D., DVM | ||
| Director | ||
| /s/ Stacey Ma Ph.D. | Date: | February 25, 2025 |
| Stacey Ma Ph.D. | ||
| Director | ||
| /s/ Kirk McDonald | Date: | February 25, 2025 |
| Kirk McDonald | ||
| Director | ||
| /s/ Denise Scots-Knight Ph.D. | Date: | February 25, 2025 |
| Denise Scots-Knight Ph.D. | ||
| Director | ||
| /s/ Kathy Turner | Date: | February 25, 2025 |
| Kathy Turner | ||
| Director | ||
| /s/ Craig Wallace | Date: | February 25, 2025 |
| Craig Wallace | ||
| Director | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.